Anthem Biosciences Reports Insider Trading Code Violations by Two Designated Persons

Anthem Biosciences Limited , a prominent player in the biosciences sector, has reported violations of its insider trading code by two designated persons, according to a recent disclosure to stock exchanges.

Details of the Violations

The company revealed that two of its employees, Srinivas L and Bhuvaneswari M, breached the company's Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons. Here are the key details of the violations:

Designated Person	Position	Violation Details
Srinivas L	Manager (Indirect Taxes)	Sold 674 equity shares during trading window closure period
Bhuvaneswari M	Deputy Manager (Administering Account Payables)	Sold 5,000 equity shares worth Rs. 41,75,000 without obtaining pre-clearance approval

Srinivas L's Case

Srinivas L sold an aggregate of 674 equity shares on two separate occasions during the trading window closure period, which began on October 1, 2025. These shares were originally allotted to him under the Company's ESOP Scheme. The transactions occurred despite explicit instructions to the pledgee not to sell the pledged shares during the restricted period.

Bhuvaneswari M's Case

Bhuvaneswari M sold 5,000 equity shares amounting to Rs. 41,75,000 on September 15, 2025, without obtaining the required pre-clearance approval. She had previously obtained approval on August 25, 2025, which was valid until August 31, 2025. Due to a medical emergency and subsequent leave, she missed the validity period and executed the transaction without renewed approval.

Company's Response

Anthem Biosciences has taken these breaches seriously. The Audit Committee, in its meeting held on November 6, 2025, resolved to:

Issue warning letters to both designated persons, instructing them to ensure strict adherence to the Code and regulatory requirements going forward.
Obtain acknowledgment letters from the individuals confirming their commitment to strictly adhere to the Company's Code of Conduct in the future.

The company has emphasized that any future violations will attract stricter disciplinary action.

Regulatory Compliance

The company has reported these violations as per the requirements of Schedule B read with Regulation 9(1) of SEBI (Prohibition of Insider Trading) Regulations, 2015. This disclosure demonstrates Anthem Biosciences' commitment to transparency and regulatory compliance in matters of insider trading.

These incidents underscore the importance of strict adherence to insider trading regulations and the need for continuous education and vigilance among designated persons in listed companies.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.14%	+3.11%	-6.05%	-10.39%	-10.39%	-10.39%

Anthem Biosciences Limited , a prominent player in the Contract Research, Development and Manufacturing Organization (CRDMO) and Speciality Ingredients sectors, has announced its financial results for the second quarter of fiscal year 2026, ending September 30, 2025.

Financial Highlights

The company reported a consolidated total income of Rs. 5,982.56 crore for Q2 FY2026, marking a 8.2% increase from Rs. 5,528.01 crore in the same quarter last year. However, profit before tax (PBT) saw an increase to Rs. 2,296.03 crore from Rs. 1,995.33 crore year-over-year, representing a 15.1% growth.

For a clearer picture of the company's performance, here's a breakdown of the key financial metrics:

Metric (in Rs. crore)	Q2 FY2026	Q2 FY2025	YoY Change
Total Income	5,982.56	5,528.01	+8.2%
Revenue from Operations	5,500.27	5,249.56	+4.8%
Profit Before Tax	2,296.03	1,995.33	+15.1%
Net Profit	1,734.28	1,619.27	+7.1%

Segment Performance

Anthem Biosciences operates through two main segments:

CRDMO (Contract Research, Development and Manufacturing Organization): This segment generated revenue of Rs. 4,658.13 crore in Q2 FY2026.
Speciality Ingredients: This segment contributed Rs. 842.14 crore to the quarterly revenue.

Half-Year Performance

For the half-year ended September 30, 2025, Anthem Biosciences reported:

Total income of Rs. 11,612.77 crore, up from Rs. 9,108.50 crore in the previous year.
Profit before tax increased to Rs. 4,158.51 crore from Rs. 3,175.09 crore year-over-year.

Balance Sheet Highlights

As of September 30, 2025, the company's financial position shows:

Total assets of Rs. 32,842.97 crore
Total equity of Rs. 27,525.45 crore
Cash and cash equivalents of Rs. 5,038.31 crore

Management Commentary

The Board of Directors approved these results in their meeting held on November 8, 2025. The company's equity shares have been listed on the National Stock Exchange of India Limited (NSE) and BSE Limited since July 21, 2025, following its Initial Public Offering (IPO).

Conclusion

Anthem Biosciences has shown growth in both revenue and profit for the quarter. The company's strong performance in the CRDMO segment and its recent listing on major stock exchanges position it as a notable player in the biosciences industry. The consistent growth in total income and profit before tax, both for the quarter and half-year, indicates positive momentum for the company.